Psilocybin

—

evidence score

other

Scheduled Substance

magic mushroomspsilocin (active metabolite)4-PO-DMT+2 more

Psilocybin is a naturally occurring tryptamine prodrug found in over 200 mushroom species. It is dephosphorylated to psilocin in vivo, which acts as a 5-HT2A agonist. The most significant development in psychiatry in decades: FDA Breakthrough Therapy designation for treatment-resistant depression (2018) and major depressive disorder (2019). Phase 3 trials show 1-2 doses produce rapid (within weeks), sustained (6-12 months) remission of treatment-resistant depression. MAPS and Compass Pathways Phase 3 trials running. Microdosing (sub-perceptual doses) is a growing area with mixed clinical data but significant anecdotal use in tech/performance communities. Oregon and Colorado have state-level regulated medical frameworks as of 2024.

Evidence

No score yet

Safety

Unknown safety profile

Clinical Status

No formal phase listed

Research Sync

Not synced yet

Dosing

Typical

25 mg

1 mgRange40 mg

Frequencysingle session or every 2-4 weeks (therapeutic); 0.1-0.3mg every 3 days (microdosing)

Set height & weight in Settings to see your dose.

Pharmacology

Half-lifePsilocin: ~3 hours; psychological effects 4-6 hours

OnsetPsychedelic effects 30-60 min; antidepressant effects within days to weeks after single session

DurationAcute: 4-6 hours; therapeutic antidepressant effects: months from single dose

Routes

oral

Evidence Score

—

0 studies indexed

Scoring Factors

Volume(40%)—

Quality(30%)—

Sample Size(10%)—

Consistency(10%)—

Replication(5%)—

Recency(5%)—

Evidence Levels

AScore ≥75 with at least 1 meta-analysis and 3+ RCTs

BScore ≥50 with at least 1 RCT or meta-analysis

CScore ≥25 — observational or animal evidence only

DScore <25 — very limited or preclinical data

Plain-English Snapshot

Psilocybin is currently categorized as a other compound.

Evidence scoring has not been fully computed yet, so interpret this profile as preliminary.

Safety scoring is incomplete. Start conservatively and monitor carefully.

Core mechanism

5-HT2A full agonist in PFC, DMN, and limbic system; increases synaptic density (rapid, AMPA-mediated); Default Mode Network (DMN) disruption; neuroplasticity via BDNF and TRKB

Practical Context

Strongest current signals

No indexed study summaries yet.

Elevated caution signals

2 severe/high side effect flags